NO303716B1 - Anvendelse av granulocyttkolonistimulerende faktor (G-CSF) til fremstilling av et preparat egnet for pulmonal administrering - Google Patents

Anvendelse av granulocyttkolonistimulerende faktor (G-CSF) til fremstilling av et preparat egnet for pulmonal administrering Download PDF

Info

Publication number: NO303716B1
Authority: NO; Norway
Prior art keywords: csf; use according; preparation; aerosol; blood
Prior art date: 1991-03-15

Application number

NO924413A

Other languages

English (en)

Norwegian (no)

Other versions

NO924413D0 (no

NO924413L (no

Inventor

Robert M Platz

Mark A Winters

Colin G Pitt

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-15

Filing date

1992-11-16

Publication date

1998-08-24

1992-11-16 Application filed by Amgen Inc filed Critical Amgen Inc

1992-11-16 Publication of NO924413D0 publication Critical patent/NO924413D0/no

1993-01-14 Publication of NO924413L publication Critical patent/NO924413L/no

1998-08-24 Publication of NO303716B1 publication Critical patent/NO303716B1/no

Links

108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 title claims abstract description 99
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 title claims abstract description 99
230000002685 pulmonary effect Effects 0.000 title claims abstract description 20
238000002360 preparation method Methods 0.000 title claims description 30
210000000440 neutrophil Anatomy 0.000 claims abstract description 47
239000000843 powder Substances 0.000 claims abstract description 11
208000004235 neutropenia Diseases 0.000 claims abstract description 6
208000015181 infectious disease Diseases 0.000 claims abstract description 5
210000004369 blood Anatomy 0.000 claims description 13
239000008280 blood Substances 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
210000004027 cell Anatomy 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
241000588724 Escherichia coli Species 0.000 claims description 3
210000000214 mouth Anatomy 0.000 claims description 3
239000012736 aqueous medium Substances 0.000 claims 2
241000894006 Bacteria Species 0.000 claims 1
239000000725 suspension Substances 0.000 claims 1
239000000443 aerosol Substances 0.000 abstract description 60
238000012384 transportation and delivery Methods 0.000 abstract description 11
238000010254 subcutaneous injection Methods 0.000 abstract description 9
239000007929 subcutaneous injection Substances 0.000 abstract description 9
239000006199 nebulizer Substances 0.000 description 27
241001465754 Metazoa Species 0.000 description 22
239000000243 solution Substances 0.000 description 22
241000699800 Cricetinae Species 0.000 description 18
210000004072 lung Anatomy 0.000 description 18
239000004094 surface-active agent Substances 0.000 description 12
239000000047 product Substances 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
230000008021 deposition Effects 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000004044 response Effects 0.000 description 8
238000009826 distribution Methods 0.000 description 6
238000000034 method Methods 0.000 description 6
241000282412 Homo Species 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
229940071648 metered dose inhaler Drugs 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
238000009423 ventilation Methods 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
231100000824 inhalation exposure Toxicity 0.000 description 3
-1 polyoxyethylene Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000003380 propellant Substances 0.000 description 3
230000000284 resting effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
102400000686 Endothelin-1 Human genes 0.000 description 2
101800004490 Endothelin-1 Proteins 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108010000817 Leuprolide Proteins 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000002950 deficient Effects 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
229960004338 leuprorelin Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
IZUAHLHTQJCCLJ-UHFFFAOYSA-N (2-chloro-1,1,2,2-tetrafluoroethyl) hypochlorite Chemical compound FC(F)(Cl)C(F)(F)OCl IZUAHLHTQJCCLJ-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
OHMHBGPWCHTMQE-UHFFFAOYSA-N 2,2-dichloro-1,1,1-trifluoroethane Chemical compound FC(F)(F)C(Cl)Cl OHMHBGPWCHTMQE-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000700198 Cavia Species 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229940082819 Luteinizing hormone releasing hormone (LHRH) agonist Drugs 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000009668 clonal growth Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
206010024378 leukocytosis Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000029983 protein stabilization Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000021309 simple sugar Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
210000002993 trophoblast Anatomy 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
230000007279 water homeostasis Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/838—Marrow; spleen

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Accessory Of Washing/Drying Machine, Commercial Washing/Drying Machine, Other Washing/Drying Machine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO924413A 1991-03-15 1992-11-16 Anvendelse av granulocyttkolonistimulerende faktor (G-CSF) til fremstilling av et preparat egnet for pulmonal administrering NO303716B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66979291A	1991-03-15	1991-03-15
PCT/US1992/002126 WO1992016192A1 (fr)	1991-03-15	1992-03-13	Administration pulmonaire d'un facteur de stimulation des populations de granulocytes

Publications (3)

Publication Number	Publication Date
NO924413D0 NO924413D0 (no)	1992-11-16
NO924413L NO924413L (no)	1993-01-14
NO303716B1 true NO303716B1 (no)	1998-08-24

Family

ID=24687763

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO924413A NO303716B1 (no)	1991-03-15	1992-11-16	Anvendelse av granulocyttkolonistimulerende faktor (G-CSF) til fremstilling av et preparat egnet for pulmonal administrering

Country Status (17)

Country	Link
US (1)	US5284656A (fr)
EP (1)	EP0505123B1 (fr)
JP (1)	JP3507486B2 (fr)
CN (1)	CN1066192A (fr)
AT (1)	ATE147270T1 (fr)
AU (1)	AU643141B2 (fr)
CA (1)	CA2082951C (fr)
DE (1)	DE69216450T2 (fr)
DK (1)	DK0505123T3 (fr)
ES (1)	ES2097866T3 (fr)
FI (1)	FI106433B (fr)
GR (1)	GR3022663T3 (fr)
IL (1)	IL101235A (fr)
NO (1)	NO303716B1 (fr)
NZ (1)	NZ241954A (fr)
WO (1)	WO1992016192A1 (fr)
ZA (1)	ZA921915B (fr)

Families Citing this family (270)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2032831T5 (es)	1986-08-19	2001-02-16	Genentech Inc	Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
US6565841B1 (en) *	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
ES2179831T3 (es) *	1992-09-29	2003-02-01	Inhale Therapeutic Syst	Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
AU685433B2 (en)	1993-02-12	1998-01-22	Regents Of The University Of Minnesota	Pulmonary administration of sCR1 and other complement inhibitory proteins
US5747445A (en) *	1993-06-24	1998-05-05	Astra Aktiebolag	Therapeutic preparation for inhalation
TW402506B (en)	1993-06-24	2000-08-21	Astra Ab	Therapeutic preparation for inhalation
US6632456B1 (en)	1993-06-24	2003-10-14	Astrazeneca Ab	Compositions for inhalation
US6794357B1 (en) *	1993-06-24	2004-09-21	Astrazeneca Ab	Compositions for inhalation
US20010003739A1 (en) *	1993-06-24	2001-06-14	Astrazeneca Ab	Systemic administration of a therapeutic preparation
IS1796B (is) *	1993-06-24	2001-12-31	Ab Astra	Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5830853A (en)	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
WO1995023862A1 (fr) *	1994-03-04	1995-09-08	Ludwig Institute For Cancer Research	Animaux a rupture genique ciblee
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
WO1995024183A1 (fr) *	1994-03-07	1995-09-14	Inhale Therapeutic Systems	Procede et preparations pour l'administration d'insuline par voie pulmonaire
EP0759939B1 (fr) *	1994-05-18	2005-07-20	Nektar Therapeutics	Procedes et compositions pour produire des interferons sous forme de poudre seche
US6165976A (en)	1994-06-23	2000-12-26	Astra Aktiebolag	Therapeutic preparation for inhalation
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US6586006B2 (en)	1994-08-04	2003-07-01	Elan Drug Delivery Limited	Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6471956B1 (en)	1994-08-17	2002-10-29	The Rockefeller University	Ob polypeptides, modified forms and compositions thereto
US6124439A (en) *	1994-08-17	2000-09-26	The Rockefeller University	OB polypeptide antibodies and method of making
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en)	1994-08-17	2002-02-26	The Rockefeller University	OB polypeptides and modified forms as modulators of body weight
US6001968A (en) *	1994-08-17	1999-12-14	The Rockefeller University	OB polypeptides, modified forms and compositions
US6124448A (en) *	1994-08-17	2000-09-26	The Rockfeller University	Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) *	1994-08-17	2000-04-11	The Rockefeller University	OB polypeptides as modulators of body weight
US6524557B1 (en)	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
SE9404468D0 (sv) *	1994-12-22	1994-12-22	Astra Ab	Powder formulations
CZ182297A3 (cs) *	1994-12-22	1998-01-14	Astra Aktiebolag	Terapeutický přípravek pro inhalaci obsahující parathyroidní hormon, PTH
ATE236617T1 (de)	1994-12-22	2003-04-15	Astrazeneca Ab	Aerosol-arzneiformulierungen
AU5710896A (en) *	1995-03-31	1996-10-16	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US6936439B2 (en) *	1995-11-22	2005-08-30	Amgen Inc.	OB fusion protein compositions and methods
US20030040467A1 (en) *	1998-06-15	2003-02-27	Mary Ann Pelleymounter	Ig/ob fusions and uses thereof.
US6471943B1 (en)	1996-12-30	2002-10-29	Battelle Pulmonary Therapeutics, Inc.	Formulation and method for treating neoplasms by inhalation
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
DE19733651A1 (de) *	1997-08-04	1999-02-18	Boehringer Ingelheim Pharma	Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
JP2001517692A (ja) †	1997-09-29	2001-10-09	インヘールセラピューティックシステムズ，インコーポレイテッド	ネブライザにおける使用のための安定化調製物
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6946117B1 (en) *	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6433040B1 (en)	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6858706B2 (en) *	1998-04-07	2005-02-22	St. Jude Children's Research Hospital	Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
DK2319928T3 (da) *	1998-10-23	2013-06-24	Kirin Amgen Inc	Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6773911B1 (en)	1998-11-23	2004-08-10	Amgen Canada Inc.	Apoptosis-inducing factor
CN100374163C (zh)	1999-01-13	2008-03-12	阿尔凯米亚肿瘤学私人有限公司	增强药物功效的组合物
US6500418B1 (en)	1999-02-12	2002-12-31	The Washington University	Stimulating neutrophil function to treat inflammatory bowel disease
NZ513935A (en) *	1999-02-17	2004-02-27	Csl Ltd	Immunogenic complexes and methods relating thereto
JP2003508491A (ja) *	1999-09-03	2003-03-04	アムジエン・インコーポレーテツド	癌および癌に関連する骨損失の予防または治療のための組成物および方法
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DE60039715D1 (de) *	1999-11-19	2008-09-11	Csl Ltd	Hcv-impfstoff zusammensetzungen
CA3016482A1 (fr)	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	Nouvelle molecule immunoregulatrice b7-h1,
PL356641A1 (en) *	1999-12-30	2004-06-28	Chiron Corporation	Methods for pulmonary delivery of interleukin-2
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
US8404217B2 (en) *	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en)	2000-05-10	2007-12-01	Alliance Pharma	Phospholipid-based powders for drug delivery
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US9066919B2 (en) *	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) *	2000-07-14	2000-08-10	Meditech Research Limited	Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US20020106368A1 (en) *	2000-07-28	2002-08-08	Adrian Bot	Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the same
US7128919B2 (en)	2000-08-08	2006-10-31	St. Jude Children's Research Hospital	Group B streptococcus polypeptides nucleic acids and therapeutic compositions and vaccines thereof
CN1970078A (zh)	2001-05-11	2007-05-30	安姆根有限公司	与tall－1结合的肽和相关分子
CA2458856C (fr) *	2001-08-27	2011-02-15	Meditech Research Limited	Protocoles therapeutiques ameliores
US7332474B2 (en) *	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
US6964761B1 (en) *	2001-12-12	2005-11-15	New York University	Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ
WO2003053411A1 (fr)	2001-12-19	2003-07-03	Nektar Therapeutics	Administration pulmonaire d'aminoglycosides
ATE389183T1 (de) *	2002-03-22	2008-03-15	Univ Muenchen L Maximilians	Zytokapazität-verfahren
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003252075A1 (en) *	2002-07-16	2004-02-02	University Of South Florida	Human immunosuppressive protein
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
AU2003266081A1 (en)	2002-09-13	2004-04-30	Universite Laval	Nucleoside triphosphate diphosphohydrolase (ntpdase 8) and uses thereof
US6919426B2 (en)	2002-09-19	2005-07-19	Amgen Inc.	Peptides and related molecules that modulate nerve growth factor activity
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
WO2004094457A2 (fr) *	2003-04-16	2004-11-04	Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University	Composition peptidomimetique rgd stable
US7919118B2 (en)	2003-05-12	2011-04-05	Affymax, Inc.	Spacer moiety for poly (ethylene glycol) modified peptide based compounds
DE602004028725D1 (de)	2003-05-12	2010-09-30	Affymax Inc	Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
ATE554108T1 (de)	2003-07-25	2012-05-15	Amgen Inc	Verfahren bezüglich ldcam und crtam
US20090226397A1 (en) *	2003-10-24	2009-09-10	Nora Therapeutics, Inc.	Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) *	2003-10-24	2012-12-25	Nora Therapeutics, Inc.	Method for reducing the risk of spontaneous abortion in a human female subject
EP2198876B1 (fr)	2003-10-24	2012-12-05	Nora Therapeutics, Inc.	Procédé de réduction du risque de survenue d'échec d'une implantation chez un sujet
WO2005042024A1 (fr) *	2003-11-04	2005-05-12	Lek Pharmaceuticals D.D.	Composition pharmaceutique stable comportant le facteur stimulant les colonies de granulocytes
WO2005112970A2 (fr)	2004-05-12	2005-12-01	The Brigham And Women's Hospital, Inc.	Utilisation de gelsoline pour le traitement d'infections
EP1773400A2 (fr) *	2004-07-08	2007-04-18	Amgen Inc.	Peptides therapeutiques
JP2008506789A (ja)	2004-07-18	2008-03-06	シーエスエル、リミテッド	インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
CN101103045B (zh) *	2004-09-24	2015-11-25	安姆根有限公司	修饰的Fc分子
MX2007004176A (es)	2004-10-06	2007-06-15	Mayo Foundation	B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
CN101142234A (zh) *	2004-11-11	2008-03-12	阿费麦克斯公司	结合红细胞生成素受体的新肽
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
US7968096B2 (en) *	2005-05-04	2011-06-28	The University Of Vermont And State Agricultural College	Methods and compositions for treating toxoplasma
US7550433B2 (en)	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) *	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
WO2007005627A2 (fr)	2005-07-01	2007-01-11	Forsyth Dental Infirmary For Children	Essais de detection d'antigenes de la tuberculose et vaccins
EP1912658B1 (fr) *	2005-07-27	2017-01-25	Alchemia Oncology Pty Limited	Protocoles thérapeutiques utilisant le hyaluronan
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
EP1922077A4 (fr) *	2005-09-07	2013-03-06	Alchemia Oncology Pty Ltd	Compositions thérapeutiques comprenant de l hyaluronane et des anticorps therapeutiques, et procédes thérapeutiques
KR20080047463A (ko) *	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
EA013468B1 (ru) *	2005-09-16	2010-04-30	Коли Фармасьютикал Гмбх	Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
WO2007035180A1 (fr)	2005-09-20	2007-03-29	New York University	Méthode pour traiter une maladie pulmonaire avec des interférons
US8105572B2 (en) *	2007-05-18	2012-01-31	New York University	Method of treating tuberculosis with interferons
KR101507027B1 (ko)	2005-10-21	2015-03-31	엘에프비 유에스에이, 인크.	항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
TW200732350A (en) *	2005-10-21	2007-09-01	Amgen Inc	Methods for generating monovalent IgG
AR056806A1 (es)	2005-11-14	2007-10-24	Amgen Inc	Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US20070124176A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080033763A1 (en) *	2005-11-30	2008-02-07	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) *	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070136092A1 (en) *	2005-11-30	2007-06-14	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080052114A1 (en) *	2005-11-30	2008-02-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational systems and methods related to nutraceuticals
US20080103746A1 (en) *	2005-11-30	2008-05-01	Searete Llc, A Limited Liability Corporation	Systems and methods for pathogen detection and response
US20070174128A1 (en) *	2005-11-30	2007-07-26	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080114577A1 (en) *	2005-11-30	2008-05-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems associated with nutraceutical related assays
US7827042B2 (en) *	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en)	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US20070289258A1 (en) *	2006-06-14	2007-12-20	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Individualized pharmaceutical selection and packaging
US7927787B2 (en) *	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US20110145009A1 (en) *	2005-11-30	2011-06-16	Jung Edward K Y	Methods and systems related to transmission of nutraceutical associatd information
US20080004905A1 (en) *	2006-06-28	2008-01-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems for analysis of nutraceutical associated components
US20070124218A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized nutraceutical selection and packaging
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
WO2007082144A2 (fr) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
US20080044405A1 (en) *	2006-02-25	2008-02-21	President And Fellows Of Harvard College	Noble metal complex-mediated immunosuppression
ES2651619T3 (es)	2006-03-15	2018-01-29	The Brigham And Women's Hospital, Inc.	Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
CN101443030A (zh)	2006-03-15	2009-05-27	布赖汉姆妇女医院有限公司	凝溶胶蛋白诊断和治疗炎性疾病的用途
WO2007124361A2 (fr) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	B7-h1 soluble
WO2007137163A2 (fr) *	2006-05-19	2007-11-29	Georgia Tech Research Corporation	Ligand des transporteurs abc
US7981425B2 (en)	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
AU2007265475B2 (en)	2006-06-26	2010-08-19	Amgen Inc.	Methods for treating atherosclerosis
DE102006030164A1 (de) *	2006-06-29	2008-01-03	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Inhalative Pulver
WO2008008873A2 (fr) *	2006-07-14	2008-01-17	Georgia Tech Research Corporation	Ligand du canal clc
NZ575437A (en)	2006-09-27	2012-02-24	Coley Pharm Gmbh	Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US7820623B2 (en)	2006-10-25	2010-10-26	Amgen Inc.	Conjugated toxin peptide therapeutic agents
AU2007339773B2 (en) *	2006-12-27	2011-03-10	The Johns Hopkins University	Compositions and methods for stimulating an immune response
US7989173B2 (en)	2006-12-27	2011-08-02	The Johns Hopkins University	Detection and diagnosis of inflammatory disorders
WO2008116470A1 (fr) *	2007-03-26	2008-10-02	Drugrecure Aps	Amélioration de la défense pulmonaire d'un hôte par l'administration d'un facteur de stimulation des colonies de granulocytes
EP2152304B1 (fr)	2007-05-02	2018-08-22	The Regents of the University of Michigan	Compositions thérapeutiques à base de nanoémulsion et leurs procédés d'utilisation
PL2170353T3 (pl) *	2007-05-18	2015-10-30	Adiutide Pharmaceuticals Gmbh	Modyfikowane fosforanami analogi oligonukleotydów wykazujące aktywność immunostymulującą
WO2008143892A1 (fr) *	2007-05-18	2008-11-27	New York University	Procédé de traitement de la tuberculose par interférons
AU2008262490B2 (en)	2007-05-22	2011-11-17	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
CA2693707A1 (fr)	2007-07-13	2009-03-05	The Johns Hopkins University	Variants de b7-dc
DK2181190T3 (da)	2007-07-26	2014-03-31	Amgen Inc	Modificerede lecithin-kolesterol-acyltransferase-enzymer
US8562967B2 (en) *	2007-08-27	2013-10-22	Biogenerix Ag	Stable liquid formulations of G-CSF
RU2010112771A (ru) *	2007-10-09	2011-11-20	Коули Фармасьютикал ГмбХ (DE)	Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
AU2008326187B2 (en)	2007-11-06	2014-12-04	Adiutide Pharmaceuticals Gmbh	Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2009075836A2 (fr) *	2007-12-10	2009-06-18	The Brigham And Women's Hospital, Inc.	Variantes de rap pour l'administration de médicaments
EP2077132A1 (fr)	2008-01-02	2009-07-08	Boehringer Ingelheim Pharma GmbH & Co. KG	Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
PL2708603T3 (pl)	2008-01-25	2017-12-29	Beth Israel Deaconess Medical Ct Inc	Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek
WO2009111315A2 (fr) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Méthodes de réduction de l’inflammation granulomateuse
AU2009223838B2 (en)	2008-03-03	2012-07-26	The University Of Miami	Allogeneic cancer cell-based immunotherapy
WO2009117116A2 (fr)	2008-03-20	2009-09-24	University Of Miami	Vaccination par protéine de choc thermique gp96 et procédés d'utilisation
US20110171168A1 (en) *	2008-05-13	2011-07-14	Nora Therapeutics, Inc.	Human g-csf analogs and methods of making and using thereof
CA2734991A1 (fr) *	2008-07-23	2010-01-28	Massachusetts Institute Of Technology	L'activation de l'histone desacetylase 1 (hdac1) protege contre des lesions de l'adn et augmente la survie neuronale
US8999661B2 (en) *	2008-07-30	2015-04-07	Dana-Farber Cancer Institute, Inc.	Compositions for detecting cell death and methods of use thereof
WO2010019271A1 (fr)	2008-08-15	2010-02-18	Georgetown University	Régulateurs fluorescents de l'expression de rassf1a et de la prolifération de cellules cancéreuses humaines
HRP20151338T1 (hr)	2008-08-22	2016-01-15	Sanofi	[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita
PL2350129T3 (pl)	2008-08-25	2015-12-31	Amplimmune Inc	Kompozycje antagonistów PD-1 i sposoby stosowania
EP2328919A2 (fr) *	2008-08-25	2011-06-08	Amplimmune, Inc.	Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse
CN102405286A (zh)	2008-09-22	2012-04-04	阿克赛医药公司	减小大小的自递送RNAi化合物
WO2010036945A2 (fr) *	2008-09-26	2010-04-01	The Regents Of The University Of Michigan	Compositions thérapeutiques du type nano-émulsion et procédés pour les utiliser
KR101700972B1 (ko) *	2008-10-21	2017-01-31	국제백신연구소	신규한 시겔라 단백질 항원 및 방법
US20120114675A1 (en)	2008-11-13	2012-05-10	Graca Luis Ricardo Simoes Da Silva	Foxp3+ natural killer t-cells and the treatment of immune related diseases
US9974844B2 (en)	2008-11-17	2018-05-22	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
WO2010068680A1 (fr)	2008-12-10	2010-06-17	Mount Sinai School Of Medicine Of New York University	Adjuvants spécifiques du lignage 17 du type lymphocytes t, compositions et méthodes
TW201034675A (en)	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
WO2010090762A1 (fr)	2009-02-04	2010-08-12	Rxi Pharmaceuticals Corporation	Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
JP5670421B2 (ja)	2009-03-31	2015-02-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	コンポーネント表面のコーティング方法
EP2432531B1 (fr)	2009-05-18	2019-03-06	Boehringer Ingelheim International GmbH	Adaptateur, dispositif d'inhalation et pulvérisateur
ES2566646T3 (es)	2009-06-16	2016-04-14	The Regents Of The University Of Michigan	Vacunas en nanoemulsión
WO2011014257A1 (fr)	2009-07-31	2011-02-03	The General Hospital Corporation	Approches pour traiter le cancer à l'aide d'inhibiteurs d'hb-egf tels que l'acide myrsinoïque a
CN102770455B (zh)	2009-08-03	2017-02-08	迈阿密大学	用于体内扩增调节性t细胞的方法
FR2955324A1 (fr)	2010-01-15	2011-07-22	Sanofi Aventis	[4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
CN102666581A (zh)	2009-08-31	2012-09-12	艾普利穆恩公司	用于抑制移植物排斥的方法和组合物
WO2011053468A1 (fr)	2009-10-30	2011-05-05	Sanofi-Aventis	Dérivés de l'acide aminobenzoïque destinés à être utilisés dans le traitement de troubles associés à la déshydrogénase
US10016568B2 (en)	2009-11-25	2018-07-10	Boehringer Ingelheim International Gmbh	Nebulizer
WO2011064164A1 (fr)	2009-11-25	2011-06-03	Boehringer Ingelheim International Gmbh	Nébuliseur
JP5658268B2 (ja)	2009-11-25	2015-01-21	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ネブライザ
EP2516418B1 (fr)	2009-12-23	2014-05-14	Sanofi	Promédicaments de [4[4-(5-aminométhyl-2-fluoro-phényl)-pipéridin-1-yl]-(1h-pyrrolo-pyridin-yl)-méthanones et leur synthèse
RU2012131280A (ru)	2009-12-23	2014-02-10	Санофи	[4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
WO2011160932A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Nébuliseur
WO2012006506A1 (fr)	2010-07-09	2012-01-12	Massachusetts Institute Of Technology	Genès, enzymes et flux constituant des cibles métaboliques pour la thérapie contre le cancer
AU2012228990B2 (en)	2011-03-16	2017-04-06	Amgen Inc.	Potent and selective inhibitors of Nav1.3 and Nav1.7
WO2012134975A1 (fr)	2011-03-28	2012-10-04	St. Jude Children's Research Hospital	Méthodes et compositions utilisant des protéines de fusion immunogènes
EP2694220B1 (fr)	2011-04-01	2020-05-06	Boehringer Ingelheim International GmbH	Appareil médical pourvu d'un récipient
WO2012149540A1 (fr)	2011-04-28	2012-11-01	The Broad Institute Inc	Inhibiteurs de l'histone désacétylase
US9827384B2 (en)	2011-05-23	2017-11-28	Boehringer Ingelheim International Gmbh	Nebulizer
HRP20190249T1 (hr)	2011-07-22	2019-04-05	Massachusetts Institute Of Technology	Aktivatori razreda i histonskih deacetilaza (hdacs) i njihova uporaba
WO2013021279A2 (fr)	2011-08-10	2013-02-14	Lfb Biotechnologies	Anticorps fortement galactosylés
US20130236484A1 (en)	2012-03-08	2013-09-12	Detectogen Inc.	Leishmaniasis antigen detection assays and vaccines
TW201400499A (zh)	2012-03-12	2014-01-01	Revo Biolog Inc	抗凝血酶用於治療妊娠毒血症之用途
WO2013152894A1 (fr)	2012-04-13	2013-10-17	Boehringer Ingelheim International Gmbh	Pulvérisateur comprenant des moyens de détrompage
US9914717B2 (en)	2012-12-20	2018-03-13	The Broad Institute, Inc.	Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
WO2014099984A1 (fr)	2012-12-20	2014-06-26	Amgen Inc.	Agonistes du récepteur apj et leurs utilisations
UY35397A (es)	2013-03-12	2014-10-31	Amgen Inc	INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US10233219B2 (en)	2013-04-12	2019-03-19	Tufts Medical Center	Methods and systems for designing and/or characterizing soluble lipidated ligand agents
PL2835146T3 (pl)	2013-08-09	2021-04-06	Boehringer Ingelheim International Gmbh	Nebulizator
EP3030298B1 (fr)	2013-08-09	2017-10-11	Boehringer Ingelheim International GmbH	Nébuliseur
PL3041958T4 (pl)	2013-09-04	2020-11-02	Cold Spring Harbor Laboratory	Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi
US10259875B2 (en)	2013-10-01	2019-04-16	Mayo Foundation For Medical Education And Research	Methods for treating cancer in patients with elevated levels of BIM
WO2015057724A1 (fr)	2013-10-14	2015-04-23	Nora Therapeutics, Inc.	Utilisation de g-csf pour traiter ou prévenir la villite d'étiologie indéterminée chez une femme
JP6306700B2 (ja)	2013-11-01	2018-04-04	ユニバーシティオブオスロＵｎｉｖｅｒｓｉｔｙｏｆＯｓｌｏ	アルブミン改変体及びその使用
WO2015071763A2 (fr)	2013-11-15	2015-05-21	Oslo Universitetssykehus Hf	Epitopes peptidiques de lymphocytes t cytotoxiques et lymphocytes t specifiques a l'antigene, procede pour leur decouverte, et leurs utilisations
WO2015167567A1 (fr)	2014-05-01	2015-11-05	Charlesson Llc	Inhibiteurs de stat3 pour le traitement de l'hyperglycémie et de troubles de la vision spatiale
ES2874029T3 (es)	2014-05-07	2021-11-04	Boehringer Ingelheim Int	Nebulizador
LT4242916T (lt)	2014-05-07	2025-12-29	Boehringer Ingelheim International Gmbh	Purkštuvas
EA032850B1 (ru)	2014-05-07	2019-07-31	Бёрингер Ингельхайм Интернациональ Гмбх	Контейнер, небулайзер и способ изготовления контейнера
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
WO2015191781A2 (fr)	2014-06-10	2015-12-17	Amgen Inc.	Polypeptides d'apéline
HUE063194T2 (hu)	2014-06-13	2024-01-28	Bach Biosciences Llc	FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
WO2016014148A1 (fr)	2014-07-23	2016-01-28	Mayo Foundation For Medical Education And Research	Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
EP3204039B1 (fr)	2014-10-10	2022-06-08	The Regents Of The University Of Michigan	Compositions de nanoémulsions permettant de prévenir, de supprimer ou d'éliminer une maladie allergique et inflammatoire
WO2016080853A1 (fr)	2014-11-21	2016-05-26	Bsim2 – Biomolecular Simulations Lda	Dérivés de 2-thioxothiazolidin-4-one actifs en tant que ligands de la transthyrétine et utilisations de ces dérivés
US9440953B2 (en)	2014-12-19	2016-09-13	OncoArendi Therapeutics Sp. z o.o.	Substituted amino triazoles useful as acidic mammalian chitinase inhibitors
PL410665A1 (pl)	2014-12-29	2016-07-04	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3242554A4 (fr)	2015-01-08	2018-06-06	The Board of Trustees of the University of Illionis	Synthèse concise de dérivés d'urée d'amphotéricine b
EP3268034A4 (fr)	2015-03-05	2018-11-14	Northwestern University	Virus non neuro-invasifs et leurs utilisations
CA3213127A1 (fr)	2015-04-15	2016-10-20	Sfunga Therapeutics, Inc.	Derives d'amphotericine b
EP3307723B1 (fr)	2015-06-15	2020-11-11	BSIM2 - Biomolecular Simulations, S.A.	Dérivés bis-furan en tant que stabilisateurs de la transthyrétine (ttr) et inhibiteurs de l'amyloïd pour le traitement de la polyneuropathie amiloïde familiale (paf)
PL415078A1 (pl)	2015-09-04	2017-03-13	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
EP3365446A4 (fr)	2015-10-19	2019-06-26	Phio Pharmaceuticals Corp.	Composés d'acides nucléiques de taille réduite à auto-administration ciblant des longs arn non codants
WO2017075045A2 (fr)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Anticorps anti-b7-h1
AU2017210118B2 (en)	2016-01-22	2023-05-04	On Target Therapeutics, LLC.	Compounds and methods for treating inflammation
WO2017177228A1 (fr)	2016-04-08	2017-10-12	The Board Of Trustees Of The University Of Illinois	Restauration médiée par les petites molécules de la physiologie des surfaces des voies respiratoires dans un épithélium pulmonaire humain atteint de mucoviscidose
PL417066A1 (pl)	2016-05-04	2017-11-06	Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory arginazy oraz ich zastosowania terapeutyczne
US20180119141A1 (en)	2016-10-28	2018-05-03	Massachusetts Institute Of Technology	Crispr/cas global regulator screening platform
WO2018096396A1 (fr)	2016-11-22	2018-05-31	University Of Oslo	Variants d'albumine et leurs utilisations
US11318190B2 (en)	2017-05-05	2022-05-03	United States Government As Represented By The Department Of Veterans Affairs	Methods and compositions for treating liver disease
US12268736B2 (en)	2017-09-07	2025-04-08	University Of Oslo	Vaccine molecules
EP3678699A1 (fr)	2017-09-07	2020-07-15	University Of Oslo	Molécules vaccinales
FI3694526T3 (fi)	2017-10-11	2025-02-06	Univ Illinois	Genotyypistä riippumaton toimintakyvyn palautus pienimolekyylisillä bikarbonaattikanavilla kystistä fibroosia varten
LT3723783T (lt)	2017-12-15	2023-03-27	Stealth Biotherapeutics Inc.	Į mitochondrijas nukreipiami peptidai
US12128018B2 (en)	2018-01-12	2024-10-29	KDAc Therapeutics, Inc.	Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer
WO2020092839A1 (fr)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Méthodes et matériaux de traitement du cancer
EP3873540A4 (fr)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	Procédés et matériaux pour le traitement du cancer
CA3146715A1 (fr)	2019-07-15	2021-01-21	Oncoarendi Therapeutics S.A.	Aminotriazoles substitues utiles en tant qu'inhibiteurs de chitinase
CA3148090A1 (fr)	2019-07-24	2021-01-28	Stealth Biotherapeutics Inc.	Compose peptidomimetique (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-i-oxopropan-2-yl)-5-guanidinopentanamide dans le traitement de maladies neurodegeneratives
US11584728B2 (en)	2019-10-04	2023-02-21	Stealth Biotherapeutics Inc.	Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
CN120554211A (zh)	2020-04-03	2025-08-29	康德生物医疗有限公司	用于预防和/或治疗线粒体疾病的组合物和方法
US11572342B2 (en)	2020-09-18	2023-02-07	Niche Biopharmaceuticals LLC	Antimicrobial and antiviral sulfur containing glycerol monoester derivatives
TW202228720A (zh)	2020-12-22	2022-08-01	波蘭商昂科艾倫迪治療法股份公司	精胺酸酶抑制劑及其使用方法
US11834408B2 (en)	2021-05-28	2023-12-05	Purdue Research Foundation	Compounds for the treatment of SARS
WO2022261347A1 (fr)	2021-06-10	2022-12-15	Stealth Biotherapeutics Inc.	Composés, compositions et procédés pour la prévention et/ou le traitement de diverses maladies ou troubles mitochondriaux, notamment la maladie de friedreich
WO2023031673A1 (fr)	2021-08-30	2023-03-09	Amazentis Sa	Traitement de la covid-19 longue au moyen d'urolithines
WO2023069255A1 (fr)	2021-10-20	2023-04-27	Stealth Biotherapeutics Inc.	Procédés et compositions comprenant des peptidomimétiques pour le traitement, la prévention, l'inhibition, l'amélioration ou le retardement de l'apparition d'affections ophtalmiques
WO2023119233A1 (fr)	2021-12-23	2023-06-29	Molecure S.A.	Inhibiteurs de la désubiquitinase et leurs procédés d'utilisation
WO2023133321A1 (fr)	2022-01-10	2023-07-13	Stealth Biotherapeutics Inc.	Peptidomimétique à petites molécules destiné au traitement de tauopathies
CA3252179A1 (fr)	2022-02-14	2023-08-17	Cornell University	Inhibiteurs de cgas et leurs utilisations
EP4269400B1 (fr)	2022-04-29	2025-07-09	Molecure SA	Inhibiteurs de ykl-40 et leurs applications thérapeutiques
US20240150362A1 (en)	2022-08-25	2024-05-09	Molecure S.A.	Substituted Pyrrolotriazines
EP4622712A1 (fr)	2022-11-23	2025-10-01	Vertex Pharmaceuticals Incorporated	Modulateurs d'amine macrocycliques substitués du récepteur 2 de l'orexine
EP4662201A1 (fr)	2023-02-08	2025-12-17	Vertex Pharmaceuticals Incorporated	Agonistes contenant un biaryle amide du récepteur d'orexine de type 2
WO2025010314A1 (fr)	2023-07-05	2025-01-09	Vertex Pharmaceuticals Incorporated	Agonistes contenant de l'urée du récepteur de l'orexine de type 2
WO2025010311A1 (fr)	2023-07-05	2025-01-09	Vertex Pharmaceuticals Incorporated	Agonistes contenant de l'urée du récepteur de l'orexine de type 2
WO2025049985A1 (fr)	2023-08-31	2025-03-06	Purdue Research Foundation	Méthodes et compositions pour le traitement du cancer à l'aide d'un inhibiteur de prm t5
WO2025101748A1 (fr)	2023-11-09	2025-05-15	Stealth Biotherapeutics Inc.	Cyclo-hexa-2,5-diène-1,4-diones destinés à être utilisés dans le traitement de la cardiomyopathie
WO2025231245A1 (fr)	2024-05-02	2025-11-06	Stealth Biotherapeutics Inc.	Utilisation de 1,4-benzoquinones substituées pour traiter des alpha-synucléinopathies
WO2026020091A1 (fr)	2024-07-19	2026-01-22	Stealth Biotherapeutics Inc.	Méthodes, composés, compositions, formulations et utilisations pour traiter une maladie mitochondriale résultant de mutations d'adn nucléaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61227526A (ja) *	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	新規なコロニー刺激因子
JPS62207226A (ja) *	1986-03-07	1987-09-11	Sumitomo Pharmaceut Co Ltd	経鼻投与用製剤
JPH0618781B2 (ja) *	1986-10-18	1994-03-16	中外製薬株式会社	感染症治療剤
US4961926A (en) *	1987-11-19	1990-10-09	Sloan-Kettering Institute For Cancer Research	Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
EP0527940A1 (fr) *	1990-05-08	1993-02-24	Liposome Technology, Inc.	Composition de medicament/lipides en poudre sechee par pulverisation directe

1992
- 1992-03-13 NZ NZ241954A patent/NZ241954A/en not_active IP Right Cessation
- 1992-03-13 AU AU17476/92A patent/AU643141B2/en not_active Ceased
- 1992-03-13 JP JP50934992A patent/JP3507486B2/ja not_active Expired - Fee Related
- 1992-03-13 CA CA002082951A patent/CA2082951C/fr not_active Expired - Lifetime
- 1992-03-13 WO PCT/US1992/002126 patent/WO1992016192A1/fr not_active Ceased
- 1992-03-14 CN CN92102497A patent/CN1066192A/zh active Pending
- 1992-03-15 IL IL10123592A patent/IL101235A/en not_active IP Right Cessation
- 1992-03-16 AT AT92302239T patent/ATE147270T1/de not_active IP Right Cessation
- 1992-03-16 EP EP92302239A patent/EP0505123B1/fr not_active Expired - Lifetime
- 1992-03-16 DE DE69216450T patent/DE69216450T2/de not_active Expired - Lifetime
- 1992-03-16 DK DK92302239.6T patent/DK0505123T3/da active
- 1992-03-16 ZA ZA921915A patent/ZA921915B/xx unknown
- 1992-03-16 ES ES92302239T patent/ES2097866T3/es not_active Expired - Lifetime
- 1992-09-29 US US07/953,208 patent/US5284656A/en not_active Expired - Lifetime
- 1992-11-13 FI FI925163A patent/FI106433B/fi not_active IP Right Cessation
- 1992-11-16 NO NO924413A patent/NO303716B1/no not_active IP Right Cessation
1997
- 1997-02-26 GR GR970400350T patent/GR3022663T3/el unknown

Also Published As

Publication number	Publication date
FI106433B (fi)	2001-02-15
CN1066192A (zh)	1992-11-18
CA2082951C (fr)	1999-12-21
AU643141B2 (en)	1993-11-04
WO1992016192A1 (fr)	1992-10-01
DE69216450D1 (de)	1997-02-20
FI925163A0 (fi)	1992-11-13
NO924413D0 (no)	1992-11-16
DE69216450T2 (de)	1997-04-30
DK0505123T3 (da)	1997-06-30
IL101235A0 (en)	1992-11-15
US5284656A (en)	1994-02-08
JP3507486B2 (ja)	2004-03-15
AU1747692A (en)	1992-10-21
GR3022663T3 (en)	1997-05-31
JPH05507944A (ja)	1993-11-11
NO924413L (no)	1993-01-14
ES2097866T3 (es)	1997-04-16
IL101235A (en)	1998-10-30
EP0505123A1 (fr)	1992-09-23
ZA921915B (en)	1993-04-28
FI925163L (fi)	1992-11-13
ATE147270T1 (de)	1997-01-15
EP0505123B1 (fr)	1997-01-08
NZ241954A (en)	1994-01-26

Publication	Publication Date	Title
NO303716B1 (no)	1998-08-24	Anvendelse av granulocyttkolonistimulerende faktor (G-CSF) til fremstilling av et preparat egnet for pulmonal administrering
US6565841B1 (en)	2003-05-20	Pulmonary administration of granulocyte colony stimulating factor
JP4338214B2 (ja)	2009-10-07	エリトロポエチンの肺投与
DE69126935T2 (de)	1997-11-20	Aerosolformulierung feste polypeptid mikroteilchen enthaltend und verfahren zu ihrer herstellung
MXPA02007229A (es)	2002-12-09	Un metodo para administrar una formulacion medicinal en aerosol.
JP2003519175A (ja)	2003-06-17	インターロイキン−２の肺送達のための方法
Tazawa et al.	2006	Granulocyte‐macrophage colony‐stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long‐term treatment with aerosolized granulocyte‐macrophage colony‐stimulating factor: a case report
CA3133422A1 (fr)	2020-10-08	Muteine de lipocaline pour le traitement de l'asthme
Siekmeier et al.	2009	Treatment of systemic diseases by inhalation of biomolecule aerosols
AU2021237761B2 (en)	2026-02-05	Liquid formulation of GM-CSF for inhalation
JPH05339164A (ja)	1993-12-21	経粘膜投与剤
WO2022005321A1 (fr)	2022-01-06	Tocilizumab inhalé pour traiter des maladies respiratoires liées à l'interleukine-6
HK1009239B (en)	2000-07-07	Use of erythropoietin for the preparation of a pharmaceutical composition for pulmonary administration or inhalation
CN1853725A (zh)	2006-11-01	白细胞介素－2经肺部的输递方法

Legal Events

Date	Code	Title	Description
2011-10-24	MM1K	Lapsed by not paying the annual fees